PDCD1 and ovarian carcinoma: In the neoadjuvant setting, cadonilimab (AK104), a tetravalent bsAbs targeting PD-1 and CTLA-4, is being evaluated in combination with neoadjuvant chemotherapy for advanced-stage ovarian cancer.